Introduction
The strong anticancer effects of cisplatin demonstrated that other metal-based compounds might have the potential to act as anticancer agents. 1, 2 The isoelectronic and isostructural with Pt(II); Au(III), is a suitable candidate to defeat cancer cells. While Au(III) analogs will easily reduce to metallic gold under physiological conditions, 3 in the early 1990s, a few gold compounds were prepared and characterized for their antitumor activity with positive results. 4, 5 Recently, using various Au(III) complexes with novel functionality has elicited more interest due to their distinct physical and chemical properties, stability under physiological conditions, and outstanding cytotoxic effects. 6, 7 The toxicity of gold complexes originates from two aspects: interactions with the negatively charged cell and subcellular membranes; and from the fact that trapped particles in vesicles are able to disrupt the membrane. 8 Using endocytotic mechanisms most of the nanoparticle bioconjugates enter the cells in a manner dependent on size and shape. [9] [10] [11] [12] [13] Following the absorption, these nanoparticles need to reach their subcellular targets to be effective. To increase the efficiency of uptake and prevent aggregation, the gold complexes can be loaded on a drug delivery system. 11 The potential of pyridine-Au(I) compounds for practical application has recently been demonstrated. 14 Spasmolytic, diuretic, anticoagulant, anticancer, and antianaphylactic activities of pyrans were reported. [15] [16] [17] Moreover, the antitumor submit your manuscript | www.dovepress.com
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Fazaeli et al activities of a series of pyridine, pyrane, and pyrimidine derivatives have been evaluated on 59 different human tumor cell lines. Some of the pyridine-based compounds are highly selective and inhibit leukemia cell lines.
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In this study, 2,4,6-trimethylpyridine was reacted with HAuCl 4 to produce trichloro(2,4,6-trimethylpyridine) Au(III) complex. To provide an eff icient amount of trichloro(2,4,6-trimethylpyridine)Au(III) inside the cells, the complex was loaded on a nanoporous MCM-41 drug delivery system. Nanoporous MCM-41 is absorbed efficiently by various mammalian cells. 13, 19 The nanoporous silica features a high surface area (1064 m 2 /g), large pore volume (0.9 mL/g), tunable pore size (2-10 nm), and good chemical stability. 13, 19 In addition, the biocompatibility of nanoporous MCM-41 with and without surface functionalization has been assayed in different procedures. 6 The authors have previously introduced nanoporous MCM-41 as an acceptable host for grafting of complexes with optical properties. 19 Saccharomyces cerevisiae was used to test the toxicity of trichloro(2,4,6-trimethylpyridine)Au(III) in vivo. It is an excellent model system to investigate mechanisms of drug resistance and toxicity. Most of the human enzymatic and cellular structures, the oxidative stress response, and the family of drug resistance pumps are also present in yeast. 20 As well as biodistribution and stability, analyses were performed in five Sprague Dawley ® rats bearing breast tumor and human serum.
Materials and methods Materials
All chemicals were purchased either from Sigma-Aldrich ® (St Louis, MO) or Merck Chemicals (Darmstadt, Germany) and used without further purification. All reactions and manipulations were carried out in an atmosphere of dry nitrogen, using standard Schlenk techniques. Solvents were dried and distilled under nitrogen prior to use, according to standard procedures. Nanoporous MCM-41 was synthesized, as previously reported. 21 Infrared spectra were recorded (KBr pellets) on a Shimadzu FTIR 4600 spectrometer (Kyoto, Japan 
cytotoxicity test in yeast cells
To test the biological properties of trichloro(2,4,6-trimethylpyridine)Au(III), a MATa type of S. cerevisiae was used. A 48-hour colony of this yeast was grown in 1% yeast extracts, 2% meat peptone, and 2% dextrose (here, glucose) (YPD) 23 
Biodistribution and stability analyses
Animal assays were performed in accordance with the United Kingdom Biological Council's Guidelines on the Use of Living Animals in Scientific Investigations. 24 Five Sprague Dawley rats (8-10 weeks of age; average body weight 320 ± 5 g) bearing breast tumor received 25 mg/kg AuCl 3 @ PF-MCM-41, or equal volume of double distilled water, to control counterparts via tail vein injection. The rats were maintained at 22°C-24°C with a 12-hour light:dark cycle, and were provided with drinking water and fed ad libitum for 24 hours. The animals were sacrificed by CO 2 asphyxiation followed by excising the tumor and taking blood for comparative analyses. Tumors were weighed, rinsed in a normal saline buffer, and crushed in liquid nitrogen. Serums were prepared from centrifugation of coagulated blood. The aqua from tumor cells and serums were assayed for emission standard peak of AuCl 3 @PF-MCM-41.
In vitro stability test
Serum samples were incubated with 2 mM of AuCl 3 @PF-MCM-41 at 37°C in shaker incubators (100 rpm) for 24 and 48 hours. The infrared (IR) analyses were carried out for AuCl 3 @PF-MCM-41, as described above.
Results
A new complex of gold(III), trichloro(2,4,6-trimethyl -pyridine)Au(III), was synthesized and analyzed for chemical structure. To provide enough of the complex inside cells, nanoporous MCM-41 drug delivery system was used to produce AuCl 3 @PF-MCM-41. Cytotoxicity of trichloro(2,4,6-trimethylpyridine)Au(III) and AuCl 3 @ PF-MCM-41 were studied in S. cerevisiae. Biodiversity and stability of AuCl 3 @PF-MCM-41 were evaluated in rats bearing breast tumor and human serums. synthesis of (2,4,6-trimethylpyridine) Au(III) complex
The title complex was prepared by reacting HAuCl 4 · 3H 2 O to corresponding ligand (1:1 equivalent ratio) in a mixture of methanol and acetonitrile at 40°C. The progress of the reaction was followed by the appearance of a very intense yellow fluorescence. The massive crystallization of the product in a form of plate crystals occurred after about 7 days at 30°C. Pyridine and its derivatives coordinated directly to the gold center in a square planer form, and neither hydrogen transfer nor polymerization occurred. [25] [26] [27] Presence of the gold(III) complex on MCM-41 was confirmed using IR and CHN.
Photoluminescence measurements and absorption spectrum
The photoluminescence properties of the gold(III) complex were measured in aqueous solution. As previously reported, Au(III) with d 8 electronic configuration adopts an assortment of square-planar geometry, which leads to ligand field transitions. 30 Au(III) center is an oxidized species, therefore, low-energy ligand to metal charge transfer (LMCT) transitions are quite common in contrast to metal to ligand charge transfer (MLCT) transitions. Figure 2 illustrates the low angle XRD patterns of PF-MCM-41 and AuCl 3 @PF-MCM-41. The cell parameters (a 0 = 2d 100 /√3) of 4.18 and 4.10 nm, were calculated for PF-MCM-41 and AuCl 3 @PF-MCM-41, respectively. Both patterns exhibit a high-intensity (100) reflection within 2θ in the range of 2°-3°. The similar d 100 spacing values indicated that the two-dimensional hexagonal nanoporous structures (P 6 mm ) of MCM-41 were maintained after introducing the gold(III) complex. 31 In comparison with MCM-41 diffraction, intensity of the grafted materials decreased significantly (a 0 = 4.36 nm); this, along with the decrease in surface areas (in situ), showed that the nanoporous channels were occupied by the gold complex. (Figures 4 and 5) .
XrD patterns
Toxicity test in vivo
The presence of different amount of nanoporous MCM-41 had no toxic effects on yeast growth (Figures 4-6 ).
Biodistribution and stability analyses
AuCl 3 @PF-MCM-41 was well tolerated in rats at a dose of 25 mg/kg. In comparison to the control group, no abnormalities in feeding and other behaviors were observed. Biodistribution studies revealed a higher tumor uptake within 24 hours compared to the blood tissue. The average tumor uptake was 3.8 to that of blood (mMol/mMol).
To investigate in vitro stability of AuCl 3 @PF-MCM-41, the treated human blood serums were analyzed with IR. The results confirmed stability of AuCl 3 @PF-MCM-41 in human serum within 24 and 48 hours.
Discussion
To maximize the toxic effects of gold(III) on cells, a new complex of gold(III), trichloro(2,4,6-trimethylpyridine) Au(III), was synthesized and grafted on nanoporous MCM-41. Its toxicity in S. cerevisiae, biodiversity in rat bearing breast tumor, and stability in human serum was evaluated in this study.
Trichloro(2,4,6-trimethylpyridine)Au(III) complex did not inhibit yeast growth as previously reported for HAuCl 4 .
32
One and a half millimolar HAuCl 4 · 3H 2 O completely retarded the growth of yeast cells, 32 whereas trichloro(2,4,6-trimethylpyridine)Au(III) at a similar concentration of gold had no toxic effect on the cells. The differentiation in toxicity of these materials most likely originates from their interactions with the negatively charged cell membranes. Based on the results reported by De la Fuente et al, 11 the aggregation of trichloro(2,4,6-trimethylpyridine)Au(III) under physiological conditions may lead to fewer inhibitory effects than HAuCl 4 on yeast cells.
To identify whether a drug delivery system changes the toxicity of trichloro(2,4,6-trimethylpyridine)Au(III), the In this study, the growth curves for yeast at a MCM-41 concentration of 0.1, 0.5, 5, and 10 mM confirmed this evidence (Figures 4-6) . Although, the OD 600 nm of the cell suspensions treated with 0.15 mM AuCl 3 @PF-MCM-41 depleted to a maximum of 0.7. Yeast cells were hypersensitive to 0.5 mM AuCl 3 @PF-MCM-41 but not susceptible to 5 and 7 mM trichloro(2,4,6-trimethylpyridine)Au(III) (Figure 4) , suggesting that the nanoporous MCM-41 makes the gold(III) complex a strong cell killing agent.
Conclusion
The combined results of this study show that the grafting of 0.2 mM trichloro(2,4,6-trimethylpyridine)Au(III) on 1.0 g MCM-41 dropped the IC 50 about 50-fold to the IC 50 of 0.25 mM. These data, in comparison with those from HAuCl 4 complex, 32 reveal the toxic effects of trichloro(2,4,6-trimethyl pyridine)Au(III) on S. cerevisiae. In addition, they confirm the role of nanoporous MCM-41 in delivery of the gold(III) complex to their target(s) in cells. The tested complexes were toxic to the cells as MCM-41 , trichloro(2,4,6-trimethylpyridine) Au(III) , AuCl 3 @PF-MCM-41. These results also confirmed zero premature release of trichloro(2,4,6-trimethylpyridine) Au(III). The toxicity of AuCl 3 @PF-MCM-41 on yeast cells comes from guaranteed transferring, preventing aggregation, and most probably reaching target biomolecules of the gold complex. Furthermore, the preliminary animal tests featured relatively good tumor uptake without utilizing a selective tumor delivery system (tumor to blood uptake ratio = 3.8).
The stability test in human serum, showed that Au(III) moiety stabilized significantly at neutral pH through an appropriate choice of ligand and interface ligand on nanoporous silica while preserving its chemical and biological properties.
Without any experimental evidence for subcellular localization of and drug release from AuCl 3 @PF-MCM-41, it is thought that the mode of action is dependent on free 
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